Analyst
Burman Capital
Equibles does not estimate personal net worth.
Shubham Agarwal is recorded as Analyst at Burman Capital. Shubham Agarwal has spoken on 3 earnings calls across 3 companies, most recently for Sakar Healthcare Limited on July 29, 2026. Those appearances were for Sakar Healthcare Limited, Entero Healthcare Solutions Limited and Aarti Pharmalabs Limited. The companies whose calls Shubham Agarwal spoke on are classified in the Healthcare sector.
“Sir, I just wanted to understand this oncology revenue going from 100 crores. So out of that incremental 100 crores, can you just help us understand how much would be the contribution of the 7-type variation approvals that you have, you know, achieved in date?”
“So my first question is on organic growth. And I asked this question last quarter as well. So if I were to take a 12 quarter average of your IPM outperformance up to Q2, FY26, I come to a number of 1.9.”
“Sir, I just wanted to understand that Bayer got an approval, USFD approval, in October of 2025 for one of their, you know, key products in the menopause and hot flashes category.”
Burman Capital
Analyst
Transcript header (unverified)
Sakar Healthcare Limited
Drug Manufacturers - Specialty & Generic · Healthcare
Entero Healthcare Solutions Limited
Medical Distribution · Healthcare
Aarti Pharmalabs Limited
Drug Manufacturers - Specialty & Generic · Healthcare
Earnings Call for the Quarter Ended June 30, 2026
Sakar Healthcare Limited
“Entero Healthcare Solutions Limited Q4 FY26 Earnings Conference Call”
Entero Healthcare Solutions Limited
“Aarti Pharmalabs Q3 and 9M FY "26 Earnings Conference Call”
Aarti Pharmalabs Limited
